Skip to main content
Equibles

ADXN · Addex Therapeutics Ltd. · Webcasts, Transcripts & Audio

Track ADXN — free

Use ADXN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADXN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.10 +0.03 (+0.98%)
Rebalance outlook locked
Market Cap
$3.65M
Shares
1.27M
Volume · Oct 5 5874 Avg daily vol (3M) 187.79K

Addex Therapeutics Ltd. Webcasts

Earnings calls, investor updates, investor days and conferences for Addex Therapeutics Ltd. (ADXN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼82.6% 186,443 CHF −7.22M CHF '22 Q2 22-06-30 ▲239% 631,977 CHF −2.68M CHF '23 Q2 23-06-30 ▼81.8% 115,277 CHF 12.88M CHF '24 Q2 24-06-30 LATEST ▼68.4% 36,375 CHF −1.84M CHF '25 Q2 25-06-30
Earnings call
FY26 · Q1
2026-04-30
Addex Therapeutics Ltd. (ADXN) Q1 2026 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-09-30
Addex Therapeutics Ltd. (ADXN) Q3 2025 Earnings Call Transcript
Positive tone Dipraglurant post-stroke / brain injury recovery GABAB PAM chronic cough program Neurosterix spin-out
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Addex Therapeutics Ltd. (ADXN) Q2 2025 Earnings Call Transcript
Positive tone GABAB PAM chronic cough program Neurosterix spin-out and M4 PAM progress Financing need for IND-enabling studies
Revenue
36,375 CHF
▼ 68.4% YoY
Diluted EPS
-0.02
▼ 115.4% YoY
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Addex Therapeutics Ltd. (ADXN) Q1 2025 Earnings Call Transcript
Confident tone GABAB PAM for chronic cough Dipraglurant repositioning for brain injury recovery Indivior partnership for substance use disorders
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-09-30
Addex Therapeutics Ltd. (ADXN) Q3 2024 Earnings Call Transcript
Confident tone GABAB PAM program for chronic cough Neurosterix spin-out and M4 PAM program Financial position and cash runway
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Addex Therapeutics Ltd. (ADXN) Q2 2024 Earnings Call Transcript
Positive tone GABAB PAM chronic cough program GABAB PAM substance use disorders (Indivior partnership) Neurosterix spin-out / Series A financing
Revenue
115,277 CHF
▼ 81.8% YoY
Diluted EPS
0.13
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Addex Therapeutics Ltd. (ADXN) Q1 2024 Earnings Call Transcript
Positive tone GABAB PAM collaboration with Indivior Neurosterix financing transaction and 20% equity stake M4 PAM program for schizophrenia (via Neurosterix)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Addex Therapeutics Ltd. (ADXN) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q2
2023-06-30
Addex Therapeutics Ltd. (ADXN) Q2 2023 Earnings Call Transcript
Revenue
631,977 CHF
▲ 239% YoY
Diluted EPS
-0.04
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Addex Therapeutics Ltd. (ADXN) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Addex Therapeutics Ltd. (ADXN) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Addex Therapeutics Ltd. (ADXN) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Addex Therapeutics Ltd. (ADXN) Q2 2022 Earnings Call Transcript
Revenue
186,443 CHF
▼ 82.6% YoY
Diluted EPS
-0.19
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Addex Therapeutics Ltd. (ADXN) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Addex Therapeutics Ltd. (ADXN) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Addex Therapeutics Ltd. (ADXN) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–16 of 16 webcasts
Key facts CIK 1574232 CUSIP 00654J206 Visit website Investor relations